Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a rare hematological malignancy classified in the non-Hodgkin's lymphoma category. Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor has been approved for use in the treatment of CLL. This drug has shown beneficial effects including a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yanhua, Lu, Hongtao, Yang, Meifeng, Xu, Chenhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831170/
https://www.ncbi.nlm.nih.gov/pubmed/31415440
http://dx.doi.org/10.1097/MD.0000000000016915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831170/
https://www.ncbi.nlm.nih.gov/pubmed/31415440
http://dx.doi.org/10.1097/MD.0000000000016915

Ejemplares similares